15-48452595-C-T
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PM1PM2PM5PP2PP3_StrongPP5
The NM_000138.5(FBN1):c.5512G>A(p.Gly1838Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000248 in 1,613,992 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 11/19 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1838D) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000138.5 missense
Scores
Clinical Significance
Conservation
Publications
- familial thoracic aortic aneurysm and aortic dissectionInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- Marfan syndromeInheritance: AD, AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, ClinGen, G2P, PanelApp Australia, Orphanet, Ambry Genetics
- Acromicric dysplasiaInheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics
- progeroid and marfanoid aspect-lipodystrophy syndromeInheritance: AD Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, Orphanet
- stiff skin syndromeInheritance: AD Classification: STRONG, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
- Weill-Marchesani syndrome 2, dominantInheritance: AD Classification: STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae)
- geleophysic dysplasiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- isolated ectopia lentisInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- neonatal Marfan syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Weill-Marchesani syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- ectopia lentis 1, isolated, autosomal dominantInheritance: AD Classification: LIMITED Submitted by: G2P
- Shprintzen-Goldberg syndromeInheritance: AD, Unknown Classification: LIMITED, NO_KNOWN Submitted by: ClinGen, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000138.5. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| FBN1 | NM_000138.5 | MANE Select | c.5512G>A | p.Gly1838Ser | missense | Exon 45 of 66 | NP_000129.3 | ||
| FBN1 | NM_001406716.1 | c.5512G>A | p.Gly1838Ser | missense | Exon 44 of 65 | NP_001393645.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| FBN1 | ENST00000316623.10 | TSL:1 MANE Select | c.5512G>A | p.Gly1838Ser | missense | Exon 45 of 66 | ENSP00000325527.5 | ||
| FBN1 | ENST00000559133.6 | TSL:1 | n.5512G>A | non_coding_transcript_exon | Exon 45 of 67 | ENSP00000453958.2 | |||
| FBN1 | ENST00000537463.6 | TSL:5 | n.*1275G>A | non_coding_transcript_exon | Exon 20 of 31 | ENSP00000440294.2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152140Hom.: 0 Cov.: 33 show subpopulations
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1461852Hom.: 0 Cov.: 32 AF XY: 0.00000275 AC XY: 2AN XY: 727232 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152140Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74304 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Marfan syndrome Pathogenic:1Uncertain:1
This variant is classified as Pathogenic. Evidence in support of pathogenic classification: Variant is present in gnomAD <0.001 for a dominant condition (v4: 4 heterozygote(s), 0 homozygote(s)); This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been classified as pathogenic, likely pathogenic and as a VUS by clinical laboratories, some of whom reported individuals with FBN1-related features (ClinVar, LOVD, personal communication). It has also been reported in the literature in individuals with FBN1-related features (PMIDs: 29510914, 29875124); Other missense variant(s) comparable to the one identified in this case have strong previous evidence for pathogenicity. Multiple alternate amino acid changes at this position have been classified by clinical laboratories in ClinVar: p.(Gly1838Cys) and p.(Gly1838Arg) as likely pathogenic, p.(Gly1838Asp) as pathogenic and as a VUS, and p.(Gly1838Ala) as a VUS; Missense variant predicted to be damaging by in silico tool(s) or highly conserved with a major amino acid change. Additional information: Variant is predicted to result in a missense amino acid change from Gly to Ser; This variant is heterozygous; This gene is predominantly associated with autosomal dominant disease; autosomal recessive forms of Marfan syndrome have rarely been reported (PMIDs: 27274304; 31950671); No published evidence of segregation with disease has been identified for this variant; No published functional evidence has been identified for this variant; Variant is located in the annotated calcium-binding EGF domain (DECIPHER); Dominant negative and loss of function are known mechanisms of disease in this gene and are associated with FBN1-related disease. Variants predicted to result in nonsense mediated decay cause loss of function effects, and are more commonly associated with severe Marfan syndrome (MIM#154700). Missense variants with both dominant negative and loss of function effects on protein function, are associated with Marfan syndrome and ectopia lentis (MIM#129600) (OMIM, PMID: 29357934). The exact genotype-phenotype correlation for this gene is still unclear, and is compounded by variable expressivity (PMID: 20301510); Variants in this gene are known to have variable expressivity. The genotype-phenotype correlations for this gene are unclear, with single variants reported in patients with a range of phenotypes (PMID: 20301510, OMIM); This variant has been shown to be maternally inherited by trio analysis.
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
The p.G1838S variant (also known as c.5512G>A), located in coding exon 44 of the FBN1 gene, results from a G to A substitution at nucleotide position 5512. The glycine at codon 1838 is replaced by serine, an amino acid with similar properties, and is located in the cb-EGF like #26 domain. This alteration was detected in an individual with a personal history of aortic or arterial aneurysms and dissections (Hicks KL et al. J Vasc Surg, 2018 Sep;68:701-711). This alteration has also been reported in subjects with features of FBN1-related disease (Ambry internal data; personal communication). Based on internal structural analysis, p.G1838S disrupts a conserved motif in a cbEGF-like domain in FBN1, and the equivalent position in other FBN1 cbEGF-like domains is disrupted by internally pathogenic variants (Handford PA et al. Nature, 1991 May;351:164-7; Lee SS et al. Structure, 2004 Apr;12:717-29; Khau Van Kien P et al. Hum Mutat, 2010 Jan;31:E1021-42). In addition, this variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Marfan Syndrome/Loeys-Dietz Syndrome/Familial Thoracic Aortic Aneurysms and Dissections Pathogenic:1
Variant summary: FBN1 c.5512G>A (p.Gly1838Ser) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251256 control chromosomes. c.5512G>A has been reported in the heterozygous state in the literature and internally in multiple individuals affected with Marfan Syndrome and or TAAD (example, Labcorp Genetics (formerly Invitae), Lauffer_2023, Yang_2023). These data indicate that the variant may be associated with disease. Further, a different amino acid change at this codon (c.5512G>T, p.Gly1838Cys) has been classified as likely pathogenic/pathogenic at Labcorp, supporting the clinical relevance of the FBN1 p.Gly1838 residue. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 29510914, 37684520, 36380655, 36517271). ClinVar contains an entry for this variant (Variation ID: 457232). Based on the evidence outlined above, the variant was classified as likely pathogenic.
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 1838 of the FBN1 protein (p.Gly1838Ser). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with FBN1-related conditions (internal data). ClinVar contains an entry for this variant (Variation ID: 457232). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt FBN1 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic.
not provided Uncertain:1
Identified in a patient with history of hepatic artery aneurysm in published literature (PMID: 29510914); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Does not affect a cysteine or calcium-binding residue within an EGF-like domain or a TGF-binding protein domain of the FBN1 gene; cysteine substitutions in the EGF-like domains represent the majority of pathogenic missense changes associated with FBN1-related disorders (PMID: 12938084); This variant is associated with the following publications: (PMID: 12938084, 29510914)
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at